Moderna (MRNA) Misses Q4 EPS by 18c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Barclays Downgrades Moderna (MRNA) to Equalweight
February 18, 2025 5:13 AM ESTBarclays analyst Gena Wang downgraded Moderna (NASDAQ: MRNA) from Overweight to Equalweight with a price target of $45.00 (from $111.00).
The analyst comments "Key takeaways. Following MRNA pre-announcement (see note), 4Q24 financial updates were largely incremental, except disclosure of norovirus Ph3 NOVA-1 (NCT06592794) clinical hold... More
Moderna (MRNA) PT Lowered to $25 at Wolfe Research
February 14, 2025 2:07 PM ESTWolfe Research analyst Alexandria Hammond lowered the price target on Moderna (NASDAQ: MRNA) to $25.00 (from $35.00) while maintaining a Underperform rating.
The analyst comments "We revised our FY2025 rev/EPS #'s downward. Cost management, Roivant litigation (potential trial in Sept), CMV... More
